BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31295769)

  • 1. Clinical outcomes according to the modified endoscopic criteria for neoadjuvant chemotherapy in resectable esophageal squamous cell carcinoma.
    Kadota T; Abe S; Yoda Y; Yoshinaga S; Oda I; Kojima T; Kato K; Daiko H; Yano T
    Dig Endosc; 2020 Mar; 32(3):337-345. PubMed ID: 31295769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma.
    Lv H; Zhang F; Huang C; Xu S; Li J; Sun B; Gai C; Liu Z; Wang M; Li Z; Tian Z
    J Cancer Res Clin Oncol; 2024 May; 150(5):260. PubMed ID: 38760614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of evaluating endoscopic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma.
    Nagai Y; Yoshida N; Baba Y; Harada K; Imai K; Iwatsuki M; Karashima R; Koga Y; Nomoto D; Okadome K; Ishimoto T; Imamura Y; Watanabe M; Baba H
    Dig Endosc; 2020 Jan; 32(1):39-48. PubMed ID: 31120560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer.
    Zhang B; Zhao H; Wu X; Gong L; Yang D; Li X; Chen X; Li J; Wang W; Wu J; Xiao Q
    Front Immunol; 2023; 14():1066527. PubMed ID: 36825006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term Outcomes of Adjuvant Nivolumab After Neoadjuvant Chemotherapy in Patients With Resected Esophageal Squamous Cell Carcinoma.
    Sugase T; Kanemura T; Takeoka T; Matsuura N; Masuike Y; Shinno N; Hara H; Kitakaze M; Kubo M; Mukai Y; Sueda T; Hasegawa S; Akita H; Nishimura J; Wada H; Yasui M; Omori T; Miyata H
    Anticancer Res; 2024 Jan; 44(1):185-193. PubMed ID: 38159967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival impact of the number of lymph nodes dissection in patients receiving neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
    Jiang D; Liu XB; Xing WQ; Chen PN; Feng SK; Yan S; Lerut T; Sun HB
    Dis Esophagus; 2023 Apr; 36(5):. PubMed ID: 36385581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma.
    Murakami Y; Hamai Y; Emi M; Hihara J; Imano N; Takeuchi Y; Takahashi I; Nishibuchi I; Kimura T; Okada M; Nagata Y
    J Radiat Res; 2018 Sep; 59(5):616-624. PubMed ID: 29939306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of incomplete neoadjuvant chemotherapy on esophageal carcinoma.
    Fujiwara Y; Lee S; Kishida S; Hashiba R; Gyobu K; Naka R; Nishiyama M; Ihara T; Takemura M; Osugi H
    Int J Clin Oncol; 2018 Oct; 23(5):877-885. PubMed ID: 29752605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy with irinotecan and nedaplatin in a single cycle followed by esophagectomy on cT4 resectable esophageal squamous cell carcinoma: a prospective nonrandomized trial for short-term outcomes.
    Tian D; Zhang L; Wang Y; Chen L; Zhang KP; Zhou Y; Wen HY; Fu MY
    Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30247659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery.
    Sugimura K; Miyata H; Shinno N; Ushigome H; Asukai K; Yanagimoto Y; Hasegawa S; Takahashi Y; Yamada D; Yamamoto K; Nishimura J; Motoori M; Wada H; Takahashi H; Yasui M; Omori T; Ohue M; Yano M
    Oncology; 2019; 97(6):348-355. PubMed ID: 31461716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral
    Yamamura K; Izumi D; Kandimalla R; Sonohara F; Baba Y; Yoshida N; Kodera Y; Baba H; Goel A
    Clin Cancer Res; 2019 Oct; 25(20):6170-6179. PubMed ID: 31358543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological tumor regression grade of metastatic tumors in lymph node predicts prognosis in esophageal cancer patients.
    Kadota T; Hatogai K; Yano T; Fujita T; Kojima T; Daiko H; Fujii S
    Cancer Sci; 2018 Jun; 109(6):2046-2055. PubMed ID: 29601131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microscopic venous invasion is a predictor of prognosis in patients with esophageal squamous cell carcinoma undergoing ineffective neoadjuvant chemotherapy and surgery.
    Tanishima Y; Takahashi K; Nishikawa K; Ishikawa Y; Yuda M; Tanaka Y; Matsumoto A; Yano F; Eto K
    Esophagus; 2023 Oct; 20(4):651-659. PubMed ID: 37081314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual Cancer Volume Predicts Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy.
    Nakao R; Konishi E; Fujiwara H; Otsuji E; Yokota I; Urata Y; Yanagisawa A
    Int J Surg Pathol; 2019 Oct; 27(7):713-721. PubMed ID: 31203677
    [No Abstract]   [Full Text] [Related]  

  • 16. Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma.
    Akiyama Y; Iwaya T; Endo F; Chiba T; Takahara T; Otsuka K; Nitta H; Koeda K; Mizuno M; Kimura Y; Sasaki A
    Surg Endosc; 2018 Jan; 32(1):391-399. PubMed ID: 28664431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Open and Thoracoscopic Esophagectomy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma After Neoadjuvant Therapy.
    Hamai Y; Emi M; Ibuki Y; Kurokawa T; Yoshikawa T; Hirohata R; Ohsawa M; Kitasaki N; Okada M
    Anticancer Res; 2021 Jun; 41(6):3011-3021. PubMed ID: 34083292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical use of tumor biomarkers in prediction for prognosis and chemotherapeutic effect in esophageal squamous cell carcinoma.
    Yang Y; Huang X; Zhou L; Deng T; Ning T; Liu R; Zhang L; Bai M; Zhang H; Li H; Ba Y
    BMC Cancer; 2019 May; 19(1):526. PubMed ID: 31151431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk prediction of esophageal squamous cell carcinoma recurrence in patients who underwent esophagectomy after receiving neoadjuvant treatment: a nationwide retrospective study in Japan.
    Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Takeuchi H; Muto M; Kakeji Y; Kitagawa Y; Doki Y
    Esophagus; 2023 Jul; 20(3):465-473. PubMed ID: 37029845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
    Hatogai K; Fujii S; Kojima T; Daiko H; Kadota T; Fujita T; Yoshino T; Doi T; Takiguchi Y; Ohtsu A
    J Surg Oncol; 2016 Mar; 113(4):390-6. PubMed ID: 27100024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.